CORPORATE HIGHLIGHTS

o       ALDA Pharmaceuticals Corp develops and markets a family of wide-spectrum biodegradable infection control products based on its proprietary T³6™ technology (patents pending). 

o       Recent financing covers corporate expenses through to projected profitability by end of 2004.

o       More than a dozen Canadian distributors, prepared for international distribution and submission to the US EPA.

o       Low float, experienced management with good corporate governance and no debt.

o       Inventory ready and ramped up to meet anticipated increase in sales.

VIRALEX™ - INITIAL INFECTION CONTROL PRODUCT

o       Viralex™ is a hospital grade, wide-spectrum, hard-surface spray disinfectant that has been tested on over 100 infectious bacteria, viruses and fungi. Viralex^TM kills them all within 3 minutes, including HIV, Hepatitis B and TB. 100 times more effective than the specified requirement for hospital use and exceeds the kill rate of other disinfectants on the market. 

o       Viralex™ has been granted a Health Canada DIN number and has also been approved by the CFIA (Canadian Food Inspection Agency) for use in food processing facilities, restaurants and other food handling establishments.

o       Viralex™ is non-corrosive, non-caustic, non-hazardous, biodegradable and highly effective, while still remaining competitively priced.

o       The emergence of SARS, Norwalk Virus, Avian Flu, drug-resistant “superbugs”, new strains of TB and other bacterial, viral and fungal pathogens has resulted in increased market demand for highly effective and non-toxic disinfectants.

T³6™ Future Product Line (late stage commercial development)

o       AldaCin – A gel disinfectant for traps and drains.

o       AldaCleanse - An anti-microbial soap effective against both bacteria and viruses.

o       AldaMould – A mould and fungal growth treatment for all applications.

 Other T³6™ products in earlier stages of development include:

o       Commercial and domestic disinfectant laundry additive.

o       Disinfectant toothpaste.

o       Periodontal ointment for treatment of gum infections.

o       Anti-fungal therapeutic treatment for cutaneous infections such as athlete’s foot.

MANUFACTURING, MARKETING AND DISTRIBUTION

o       Health Canada GMP-certified facility can produce up to 6 million units of Viralex™ per year. 

o       Growing list of distributors that supply Viralex™ to hospitals, dental offices, laboratories, chronic care facilities, medical product manufacturers, fire fighters, the military, beauty and hair salons as well as hydroelectric, water management, and telecommunications industries.

o       Viralex™ is also sold directly to key clients, including the RCMP, community police forces, the BC Ministry of Health and the BC Ambulance Service.

MARKET OPPORTUNITY

The outbreak of SARS and continuing concerns with other infectious diseases has highlighted the need for effective infection control. The worldwide market for infection control products is projected at ~$200 Billion USD. Hard surface disinfectants alone will command ~$10 Billion USD. ALDA is well positioned to expand its market for Viralex™ internationally, as well as introduce other infection control products already in the pipeline.

ALDA’s competitive advantage rests in its ability to completely denature and destroy infectious organisms using only non-toxic, non-corrosive and biodegradable ingredients. Some of ALDA’s competitors have had products banned because of corrosive or toxic chemicals.  ALDA intends to expand its marketing efforts to ensure corporate awareness and product recognition.

CASH PROJECTIONS & FINANCIAL REQUIREMENTS

Based on management’s current projections for sales of Viralex™, including expansion into the US and international markets, along with introduction of at least one new product, the anticipated cash flow projections for ALDA over the next 3 years are as follows:

Working Capital:                                 CDN ~$1,000,000 (as at November 30, 2003)

Long Term Debt:                          Nil

Recent Financing:             $1.2 Million Cdn.

Shares Outstanding:             12,784,404  (4,876,475 of which are escrowed)

Fully Diluted after Financing:             ~ 21,000,000 (assumes exercise of all warrants and options)

Contact:             Terrance G. Owen, Ph.D., M.B.A., President /CEO

           635 Columbia St., New Westminster, BC   V3M 1A7

           Phone: 604-521-8300              Fax: 604-521-8322     
                      E-mail: terry@aldapharma.com
                        Investor Relations (Toll-Free) 888-998-8886